Á lódáil...
Ibrutinib in Gynecological Malignancies and Breast Cancer: A Systematic Review
Ibrutinib is an orally available, small-molecule tyrosine kinase inhibitor. Its main purpose is to inhibit Bruton’s tyrosine kinase (BTK), an enzyme that is crucial in B cell development. It is FDA approved for the treatment of certain hematological malignancies. Several promising off-target drug ef...
Na minha lista:
| Foilsithe in: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
MDPI
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7312555/ https://ncbi.nlm.nih.gov/pubmed/32532074 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21114154 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|